<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02422927</url>
  </required_header>
  <id_info>
    <org_study_id>UPerugia01</org_study_id>
    <nct_id>NCT02422927</nct_id>
  </id_info>
  <brief_title>Nutraceutical Combination in Patients With Low-grade Systemic Inflammation</brief_title>
  <official_title>Effect of a Nutraceutical Combination on Endothelial Injury and C-reactive Protein in Patients With Low-grade Systemic Inflammation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Of Perugia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Of Perugia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators tested if a nutraceutical combination with red yeast rice, berberine and
      policosanol (NC) can significantly modify inflammation, lipid profile and markers of
      endothelial injury (endothelial microparticles) in subjects with elevated levels of
      high-sensitivity C-reactive protein (hsCRP).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Will be included in the study 100 subjects with suboptimal LDL cholesterol levels (LDL
      100-160 mg / dL) and hsCRP levels&gt; 2 mg / L, divided into two groups of equal numbers,
      matched by by sex and age, randomized to receive a nutraceutical combination containing red
      yeast 200 mg, berberine 500 mg and policosanol 10 mg (NC) in combination with a
      low-cholesterol diet (&lt;200 mg / day) or a low-cholesterol diet only (Standard of Care - SOC).

      All subjects at the time of inclusion in the study protocol will be prescribed the SOC for a
      period of 30 days (Lipid Stabilization Period: LSP); After 30 days LSP it will be performed
      randomization in the two intervention arms: NC + SOC or SOC.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in LDL cholesterol at 3 months</measure>
    <time_frame>3 months after treatment randomization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Circulating endothelial microparticles at 3 months</measure>
    <time_frame>3 months after treatment randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in C-reactive protein at 3 months</measure>
    <time_frame>3 months after treatment randomization</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Atherosclerosis</condition>
  <condition>Inflammation</condition>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Standard of Care + Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>low-cholesterol/low-saturated fat diet and a regular aerobic physical activity schedule + once daily placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nutraceutical combination</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>low-cholesterol/low-saturated fat diet and a regular aerobic physical activity schedule + Nutraceutical combination</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Nutraceutical Combination</intervention_name>
    <description>red yeast rice extract 200 mg (equivalent to 3 mg monacolins), policosanol 10 mg, berberine 500 mg, 0.2 mg folic acid, coenzyme Q10 2 mg, and astaxanthin 0.5 mg once daily</description>
    <arm_group_label>Nutraceutical combination</arm_group_label>
    <other_name>Armolipid Plus, Rottapharm-Madaus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <description>low-cholesterol/low-saturated fat diet and regular aerobic physical activity schedule</description>
    <arm_group_label>Standard of Care + Placebo</arm_group_label>
    <arm_group_label>Nutraceutical combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>Standard of Care + Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  LDL cholesterol &lt;160 mg/dl (4,14 mmol/l);

          -  hsCRP &gt;2 mg/L;

        Exclusion Criteria:

          -  triglycerides &gt;500 mg/dL (5.6 mmol/L);

          -  current or previous treatment with lipid-lowering drugs or with other drugs supposed
             to modify vascular damage and/or repair (antiplatelet, anti-hypertensive and
             antioxidant drugs);

          -  current or previous treatment with hormone replacement therapy for menopause vasomotor
             symptoms;

          -  evidence of liver dysfunction or alanine-aminotransferase (ALT) levels twice above the
             upper normal limit;

          -  creatin-kinase (CK) levels thrice above the upper normal limit

          -  history or clinical evidence of previous or current cardiovascular disease;

          -  presence of strong cardiovascular risk factors such as: serum creatinine levels &gt;2
             mg/dL, diabetes mellitus, uncontrolled systemic arterial hypertension (systolic blood
             pressure &gt;190 mg/dL or diastolic blood pressure &gt;100 mg/dL); history of cancer in the
             former 5 years before recruitment; not adequately treated hypothyroidism (TSH levels
             &gt;1,5 times the upper normal limit);

          -  history of malignancy in the previous 5 years before screening;

          -  not adequately treated hypothyroidism (TSH levels &gt;1,5 times the upper normal limit);

          -  previous or current alcohol or drugs abuse;

          -  history or clinical evidence of chronic inflammatory disease such as severe arthritis,
             systemic lupus erythematosus or chronic inflammatory bowel disease;

          -  current or previous use of immunosuppressant agents or long term glucocorticoids

          -  history or clinical evidence of any severe concomitant disease which may compromise
             subject's safety or its possibility to carry out the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matteo Pirro, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Perugia, Italy</affiliation>
  </overall_official>
  <reference>
    <citation>McGorrian C, Yusuf S, Islam S, Jung H, Rangarajan S, Avezum A, Prabhakaran D, Almahmeed W, Rumboldt Z, Budaj A, Dans AL, Gerstein HC, Teo K, Anand SS; INTERHEART Investigators. Estimating modifiable coronary heart disease risk in multiple regions of the world: the INTERHEART Modifiable Risk Score. Eur Heart J. 2011 Mar;32(5):581-9. doi: 10.1093/eurheartj/ehq448. Epub 2010 Dec 22.</citation>
    <PMID>21177699</PMID>
  </reference>
  <reference>
    <citation>Pirro M, Bergeron J, Dagenais GR, Bernard PM, Cantin B, Després JP, Lamarche B. Age and duration of follow-up as modulators of the risk for ischemic heart disease associated with high plasma C-reactive protein levels in men. Arch Intern Med. 2001 Nov 12;161(20):2474-80.</citation>
    <PMID>11700160</PMID>
  </reference>
  <reference>
    <citation>Gerli R, Sherer Y, Vaudo G, Schillaci G, Gilburd B, Giordano A, Bocci EB, Allegrucci R, Marchesi S, Mannarino E, Shoenfeld Y. Early atherosclerosis in rheumatoid arthritis: effects of smoking on thickness of the carotid artery intima media. Ann N Y Acad Sci. 2005 Jun;1051:281-90.</citation>
    <PMID>16126969</PMID>
  </reference>
  <reference>
    <citation>Gerli R, Vaudo G, Bocci EB, Schillaci G, Alunno A, Luccioli F, Hijazi R, Mannarino E, Shoenfeld Y. Functional impairment of the arterial wall in primary Sjögren's syndrome: combined action of immunologic and inflammatory factors. Arthritis Care Res (Hoboken). 2010 May;62(5):712-8. doi: 10.1002/acr.20117.</citation>
    <PMID>20191479</PMID>
  </reference>
  <reference>
    <citation>St-Pierre AC, Cantin B, Bergeron J, Pirro M, Dagenais GR, Després JP, Lamarche B. Inflammatory markers and long-term risk of ischemic heart disease in men A 13-year follow-up of the Quebec Cardiovascular Study. Atherosclerosis. 2005 Oct;182(2):315-21.</citation>
    <PMID>16159604</PMID>
  </reference>
  <reference>
    <citation>Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, Gotto AM Jr; Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001 Jun 28;344(26):1959-65.</citation>
    <PMID>11430324</PMID>
  </reference>
  <reference>
    <citation>Pirro M, Schillaci G, Paltriccia R, Bagaglia F, Menecali C, Mannarino MR, Capanni M, Velardi A, Mannarino E. Increased ratio of CD31+/CD42- microparticles to endothelial progenitors as a novel marker of atherosclerosis in hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2006 Nov;26(11):2530-5. Epub 2006 Aug 31.</citation>
    <PMID>16946129</PMID>
  </reference>
  <reference>
    <citation>Pirro M, Schillaci G, Bagaglia F, Menecali C, Paltriccia R, Mannarino MR, Capanni M, Velardi A, Mannarino E. Microparticles derived from endothelial progenitor cells in patients at different cardiovascular risk. Atherosclerosis. 2008 Apr;197(2):757-67. Epub 2007 Aug 27.</citation>
    <PMID>17720166</PMID>
  </reference>
  <reference>
    <citation>Affuso F, Ruvolo A, Micillo F, Saccà L, Fazio S. Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study. Nutr Metab Cardiovasc Dis. 2010 Nov;20(9):656-61. doi: 10.1016/j.numecd.2009.05.017. Epub 2009 Aug 20.</citation>
    <PMID>19699071</PMID>
  </reference>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2015</study_first_submitted>
  <study_first_submitted_qc>April 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2015</study_first_posted>
  <last_update_submitted>April 16, 2015</last_update_submitted>
  <last_update_submitted_qc>April 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Of Perugia</investigator_affiliation>
    <investigator_full_name>Matteo Pirro</investigator_full_name>
    <investigator_title>M.D., PhD</investigator_title>
  </responsible_party>
  <keyword>C-Reactive Protein</keyword>
  <keyword>Endothelial Microparticles</keyword>
  <keyword>Endothelium</keyword>
  <keyword>Nutraceutical</keyword>
  <keyword>Cholesterol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

